GGrantIndex
← Search

Molecular Mechanisms of Cancer

$51,642P30FY2024CANIH

University Of Chicago, Chicago IL

Investigators

Linked publications, trials & patents

Paper 39661064Paper 39579248Paper 39438113Paper 39374047Paper 39270007Paper 39141403Paper 39114540Paper 39108474Paper 39071306Paper 39069988Paper 38883758Paper 38881356Paper 38849889Paper 38810242Paper 38771643Paper 38752924Paper 38735044Paper 38716867Paper 38691450Paper 38632339Paper 38561491Paper 38548994Paper 38536082Paper 38533736Paper 38496521Paper 38427437Paper 38421866Paper 38381713Paper 38294692Paper 38294689Paper 38293065Paper 38219706Paper 38213818Paper 38190286Paper 38186960Paper 38175791Paper 38155245Trial NCT02573363Trial NCT02573220Trial NCT02542202Trial NCT02540876Trial NCT02485535Trial NCT02420210Trial NCT02399371Trial NCT02389517Trial NCT02366819Trial NCT02333188Trial NCT02333162Trial NCT02275533Trial NCT02258659Trial NCT02213913Trial NCT02199665Trial NCT02122172Trial NCT02046421Trial NCT02012296Trial NCT01949740Trial NCT01861301Trial NCT01696955Trial NCT01576172Trial NCT01307618Trial NCT01281176Trial NCT01278615Trial NCT01267266Trial NCT01256385Trial NCT01208051Trial NCT01174264Trial NCT01122888Trial NCT01076543Trial NCT01064622Trial NCT00859937Trial NCT00720174Trial NCT00504153Trial NCT00436579Trial NCT00387335Trial NCT00381641Trial NCT00376688Trial NCT00369551Trial NCT00351975Trial NCT00303862Trial NCT00290472Trial NCT00265798Trial NCT00126542Trial NCT00095784Trial NCT00091026Trial NCT00087373Trial NCT00062075Trial NCT00058019Trial NCT00055913Trial NCT00039416Trial NCT00027703Trial NCT00023946Patent 7192711Patent 6870037Patent 6482934Patent 6387619Patent 6043216Patent 5916752Patent 5786344Patent 5698686Patent 5618917

Abstract

PROJECT SUMMARY/ABSTRACT - MOLECULAR MECHANISMS OF CANCER (MMC) The overarching goal of the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) Molecular Mechanisms of Cancer (MMC) Program is to catalyze collaborative efforts that leverage emerging scientific discoveries from the laboratories of MMC scientists and propel them in a translational direction that makes an impact on cancer prevention, diagnosis, and treatment for patients living in our catchment area and beyond. The University of Chicago is a hotbed of scientific innovation, and the MMC continues to maximize the health benefits that emerge from this science, informed by the people most affected by cancer in our community. The MMC Program is centered on three key scientific and cancer- focused research themes: (1) deregulated gene expression and epigenetic defects in cancer; (2) altered cell growth and transformation; and (3) the tumor microenvironment in tumor growth and metastasis. These intersecting themes encompass the research of all members, across organ sites. The breadth and multi- disciplinary nature of our research contributes to the success of MMC in establishing productive translational collaborations both within MMC and across the other UCCCC programs. The MMC Program consists of 51 faculty members from 13 Departments, including 14 talented new faculty recruited to the institution in this funding cycle. In addition to increasing membership by 38% in this cycle, we increased the number and percentage of high-impact publications from 20% to 38% of total publications, increased NCI funding from $3.5M to $5M and launched 6 new working groups and multiple team science initiatives. Importantly, we have had increased success in moving our cutting-edge science into clinical trials, clinical applications, and/or commercialization. MMC leadership has fostered these successes by enhancing inter- programmatic collaborations, particularly with the UCCCC Clinical & Experimental Therapeutics Program via new working groups and targeted funding. Our work has a bidirectional relationship with the residents of our catchment area, who are negatively impacted by disparities in cancer incidence and mortality rates. Our work is informed by the community through multiple channels. In turn, our faculty and trainees are engaged in numerous educational and outreach opportunities to support our community. In this cycle, MMC will advance diversity, equity, and inclusion efforts by continuing to build an inclusive environment, increasing racial and gender diversity, and developing and retaining underrepresented minorities and women. Fostering the next generation of cancer researchers through extensive and interwoven education and training is a recognized hallmark of the MMC program that ensures our mission to reduce cancer burden and disparities.

View original record on NIH RePORTER →